Movement Alert|Madrigal Pharmaceuticals Intraday Rise 7.31%, AASLD real-world data reinforced Rezdiffra commercial outlook

Market Focus11-10

On November 10, Madrigal Pharmaceuticals rose 7.31% in Regular Trading, trading at $429.2 per share, with turnover of $86.07 million.

The move followed new AASLD data showing that, in real-world studies, up to 93% of patients treated with Rezdiffra experienced improvement or stabilization in liver stiffness on ultrasound elastography, with many shifting into lower liver stiffness categories, alongside improvements in cardiometabolic health markers.

Recent supporting context has also been constructive: the company reported third-quarter EPS of $1.83 and revenue of $431.268 million, both above consensus, ended the quarter with $961.8 million in cash and investments, and received a price-target increase to $743 from $709 while maintaining a Buy rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment